Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.

Shani Paluch-Shimon,Patrick Neven,Jens Huober,Irfan Cicin,Matthew P Goetz,Chikako Shimizu,Chiun-Sheng Huang, Hans Joachim Lueck,Jane Beith,Eriko Tokunaga, Jessica Reyes Contreras, Rosane Oliveira de Sant'Ana,Ran Wei,Ashwin Shahir,Sarah C Nabinger,Tammy Forrester,Stephen R D Johnston,Nadia Harbeck

Therapeutic advances in medical oncology（2023）

引用 1|浏览40

暂无评分

摘要

Abemaciclib with ET demonstrated clinically meaningful treatment benefit for IDFS and DRFS ET alone regardless of menopausal status and first ET, with a numerically greater benefit in the premenopausal compared to the postmenopausal population. Safety data in premenopausal patients are consistent with the overall safety profile of abemaciclib.

查看译文

关键词

abemaciclib,early breast cancer,high risk,monarchE,premenopausal

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要